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INTRODUCTION
This chapter makes treatment recommendations for
children aged 1 to 18 years with nephrotic syndrome, who
do not achieve a complete remission with cortico-
steroid therapy, i.e., SRNS. This chapter does not apply to
children with SRNS under 1 year of age, nor to SRNS
due to histologic patterns of glomerular injury other
than MCD, MPGN, or FSGS. The cost implications
for global application of this guideline are addressed in
Chapter 2.
4.1: Evaluation of children with SRNS
4.1.1: We suggest a minimum of 8 weeks treatment
with corticosteroids to define steroid resis-
tance. (2D)
4.1.2: The following are required to evaluate the
child with SRNS (Not Graded):
K a diagnostic kidney biopsy;
K evaluation of kidney function by GFR or
eGFR;
K quantitation of urine protein excretion.
BACKGROUND
SRNS generally, and FSGS specifically, is associated with a
50% risk for ESRD within 5 years of diagnosis if patients do
not achieve a partial or complete remission.86 Persistent
nephrotic syndrome is associated with poor patient-reported
quality of life, thromboembolic events, hypertension, perito-
nitis and other serious infections, persistent dyslipidemia,
and death.92–95 Children reaching ESRD have a greatly
reduced life expectancy, 19 years on average following
initiation of dialysis, and approximately 40 years following
transplantation.96
The cumulative burden of ongoing disease-related com-
plications must be measured against potential medication-
associated toxicities due to corticosteroids and other
immunosuppressive agents. These issues are discussed in
Chapter 3, SSNS and in Chapter 1, Introduction.
The potential benefit of therapy includes disease cure,
control of nephrotic syndrome, and/or or slowing the
progression to ESRD. There are times when the nephrologist,
with the child’s family or caregivers, will have to accept that a
point of futility has been reached, characterized by unremit-
ting and progressive loss of kidney function, resistance to
multiple drug therapies, or concern for cumulative drug-
associated toxicities.
RATIONALE
K Management of children with SRNS requires confirma-
tion of resistance to corticosteroids, usually defined by
unresponsiveness to oral prednisone or prednisolone* for
a minimum of 8 weeks.
K Kidney biopsy is necessary to exclude secondary causes of
nephrotic syndrome, and assess the extent of interstitial
and glomerular fibrosis.
K Kidney function, measured by eGFR, at presentation and
its deterioration over time is associated with the long-
term risk for kidney failure.
K Quantification of proteinuria is essential, since this provides
the comparison for subsequent treatment responsiveness.
*Prednisone and prednisolone are equivalent, used in the same
dosage, and have both been used in RCTs depending on the country
of origin. All later references to prednisone in this chapter refer to
prednisone or prednisolone. All later references to oral cortico-
steroids refer to prednisone or prednisolone.
Steroid Resistance
The minimum requirement of corticosteroid exposure to define
resistance remains unclear. Variations in the definition of SRNS
create difficulties in comparing therapeutic trials. Based upon
the International Study of Kidney Disease in Children (ISKDC),
95% of children with SSNS will demonstrate resolution of
proteinuria with 4 weeks of daily corticosteroid therapy and
100% after an additional 3 weeks of alternate-day therapy.27
Subsequent studies have reported additional remissions after an
extended exposure to steroids in low-dose prednisone control
arms within RCTs and after high doses of i.v. or oral cortico-
steroids in observational studies.97,98 It is not clear if these
late responses are due to the extended corticosteroid exposure,
a late effect of prior therapy, or natural history of the disease.
Consequently, we have elected to utilize one of the commonly
used definitions of resistance, i.e., a minimum exposure of
8 weeks of prednisone 2mg/kg/d or 60mg/m2/d for 4 weeks
followed by 1.5mg/kg or 40mg/m2 per dose alternate-day
for 4 weeks.99 At this point, steroid resistance dictates the
requirement for kidney biopsy to define the histopathology.
Steroids may be continued for an additional 4 weeks, totaling
12 weeks, while awaiting histopathology results.
Kidney Biopsy
A kidney biopsy in the evaluation of SRNS is recom-
mended. This evaluation—including light microscopy,
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immunofluorescence, and electron microscopy—may indi-
cate disorders that also result in the clinical features of the
nephrotic syndrome, e.g., immunoglobulin A nephropathy
(IgAN) or LN. The therapy is subsequently dictated by the
underlying diagnosis. (See Chapters 10 and 12 for IgAN and
LN, respectively.) Alternately, it may show pathologic lesions
of FSGS or, despite steroid resistance, still show MCD. In
Chapter 2 it was noted that 20 glomeruli are needed in a
biopsy to confidently exclude lesions that are affecting only
5% of them; hence, there is a possibility of missing an FSGS
lesion in many routine biopsies containing fewer than this
number. The kidney biopsy will also provide information
regarding the degree of interstitial and glomerular fibrosis,
which will be utilized in the assessment of prognosis of
children with SRNS. Results of the biopsy are also often used
to explain to both patient and family why there has not been
a response to therapy, and that the prognosis is likely to be
substantially altered from the initial one.
Laboratory Assessment
Kidney function should be measured at the time a diag-
nosis of SRNS is made to inform prognosis and assessment
of response to subsequent therapy. Despite the inaccuracies
in eGFR determination in the presence of nephrotic
syndrome, kidney function at the time of diagnosis is a
predictor of the long-term risk for kidney failure. Protein-
uria should be quantified by uPCR to allow subsequent
treatment response to be defined as partial, complete, or
no remission (Table 1, Chapter 3).86,100–103 The uPCR should
be measured in a first morning void to prevent variation
based upon orthostatic effects.104 Measurements of 24-hour
urine protein may also be used but such collections are
impractical in young children who are not toilet-trained.
Observational studies of patients with FSGS demonstrate
a 5-year kidney survival of 90% in patients with a complete
remission following any single or combination of tested
therapies.86,103 Partial remission has been associated with an
intermediate 5-year kidney survival of 80% in adults,
although these data are not available for children.103 Absence
of remission predicts a 5-year kidney survival of approxi-
mately 50%.86,100,103
Many genetic mutations have been identified in subjects
with SRNS and FSGS. In children with SRNS over 1 year of
age, podocin mutations have been reported in 0-30%. The
significant variation in the prevalence of SRNS-associated
mutations is exemplified by the absence of podocin
mutations in an African-American cohort of 18 children
with FSGS105 and the findings of a 28% prevalence of
podocin mutations in a European cohort of 25 children
published by the same group of investigators.106 Routine
evaluation for genetic mutations is not recommended in this
guideline due to the variable availability of genetic testing,
significant cost, low to absent prevalence observed in some
populations, and the lack of systematic studies of treatment
response and prognosis relative to specific genetic poly-
morphisms.
4.2: Treatment recommendations for SRNS
4.2.1: We recommend using a calcineurin inhibitor
(CNI) as initial therapy for children with
SRNS. (1B)
4.2.1.1: We suggest that CNI therapy be conti-
nued for a minimum of 6 months and
then stopped if a partial or complete
remission of proteinuria is not
achieved. (2C)
4.2.1.2: We suggest CNIs be continued for a
minimum of 12 months when at least
a partial remission is achieved by
6 months. (2C)
4.2.1.3: We suggest that low-dose cortico-
steroid therapy be combined with
CNI therapy. (2D)
4.2.2: We recommend treatment with ACE-I or ARBs
for children with SRNS. (1B)
4.2.3: In children who fail to achieve remission with
CNI therapy:
4.2.3.1: We suggest that mycophenolate mofetil
(2D), high-dose corticosteroids (2D),
or a combination of these agents (2D)
be considered in children who fail to
achieve complete or partial remission
with CNIs and corticosteroids.
4.2.3.2: We suggest that cyclophosphamide not
be given to children with SRNS. (2B)
4.2.4: In patients with a relapse of nephrotic syn-
drome after complete remission, we suggest
that therapy be restarted using any one of the
following options: (2C)
K oral corticosteroids (2D);
K return to previous successful immuno-
suppressive agent (2D);
K an alternative immunosuppressive agent to
minimize potential cumulative toxicity (2D).
BACKGROUND
The risk for kidney failure in patients with persistent
nephrotic syndrome provides the rationale for utilizing an
alternate therapy once steroid resistance has been established.
Both cyclosporine and corticosteroids have a direct effect on
the podocyte cytoskeleton,107 in addition to their immune-
modulating properties, indicating these agents may have mul-
tiple beneficial mechanisms of action in nephrotic syndrome.
RATIONALE
K There is moderate-quality evidence that cyclosporine
induces complete or partial remission in a majority of
children with SRNS.
K There is low-quality evidence that tacrolimus has a
similar impact on proteinuria control and may improve
adherence to treatment, based upon lower risk for
hypertrichosis and gingival hyperplasia compared to
cyclosporine.
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K There is moderate-quality evidence that treatment with
renin-angiotensin system (RAS) blockade is associated
with a reduction in proteinuria.
K The risk for kidney failure is significantly greater for
patients who fail to achieve a partial or complete
remission with any single or combination therapy.
CNI Therapy
Cyclosporine has been most widely studied for treatment of
SRNS. In three RCTs with 49 patients, 26 treated with
cyclosporine and 23 with placebo or control therapy108–110
(Table 5), cyclosporine resulted in a complete remission in
31% and partial remission in 38% during 6 months of therapy.
The 69% cumulative complete and partial remission was
significantly better than the 0-16% remission in the control
arms of these randomized studies. In a single RCT of 138
children and adults comparing cyclosporine (N¼ 72) to
mycophenolate combined with high-dose oral dexamethasone
(N¼ 66), cyclosporine resulted in a 19.4% complete remission
and 26.4% partial remission during 12 months of therapy.111
Based upon case series, complete and partial remissions are
less common in the presence of nephrotic syndrome associated
with podocin mutations. However, remissions have been
reported, and suggest that a trial of CNI therapy may induce at
least a partial remission even in these patients.112
Tacrolimus has been compared to cyclosporine in one
study with 41 total participants113 and showed no significant
difference in control of proteinuria. In this trial, the
frequency of nephrotoxicity, hypertension, and diabetes
mellitus were not different between cyclosporine and
tacrolimus. The only difference in these agents was in the
side-effect profile of hypertrichosis (95% vs. 0%, P o0.001)
and gingival hyperplasia (60% vs. 5%, P o0.001) cyclo-
sporine vs. tacrolimus, respectively, which may significantly
impact adherence to treatment recommendations.
The optimal duration of CNI therapy is unknown.
Published RCTs in children have utilized 6- and 12-month
treatment phases. Reduction in proteinuria has been docu-
mented to occur in 4.4±1.8 weeks,109 with median times to
complete and partial remission of 8 and 12 weeks.113 Relapse
in up to 70% of those responding to CNI therapy has been
documented after discontinuation of 6- and 12-month
courses of therapy. Extension of therapy beyond 12 months
to prevent relapse is common practice; however, the impact
of this approach on relapse risk, long-term kidney function,
and risk for nephrotoxicity has not been established. Drug
level monitoring is common but optimal levels are unknown
for SRNS.
No studies have evaluated cyclosporine alone vs. cyclospo-
rine with low-dose prednisone. Consequently, the necessity of
corticosteroids as an adjunct to CNI for SRNS is unknown.
A low-dose corticosteroid is recommended here to be consistent
with the majority of clinical trials. Tapering of the dose to the
lowest level that maintains remission is recommended.
The impact of podocyte-altering genetic polymorphisms
on response to immunomodulating therapy has been
reported in small genetic SRNS cohort studies with response
ranging from 7% to 80% of cohorts (ranging between 4 and
34 subjects).112 No RCTs of SRNS have evaluated the impact
of underlying genetic polymorphisms.114
RAS Blockade
RAS blockade in addition to CNI therapy is recommended
to reduce proteinuria in SRNS. Two RCTs demonstrated a
reduction in proteinuria with ACE-I therapy using enalapril115
and fosinopril.116 A dose-response reduction of proteinuria
has been observed: a 33% reduction in proteinuria with
a 0.2mg/kg dose of enalapril, and a 52% reduction in
proteinuria with a 0.6mg/kg dose of enalapril.115
Epidemiologic evidence from retrospective cohort studies
in adults and children with FSGS99,103 has demonstrated
the risk for kidney failure is significantly greater for patients
who fail to achieve a partial or complete remission of
proteinuria. There are only two published RCTs that provide
evidence of the combination of cyclosporine and RAS
blockade in SRNS.
ALTERNATIVE THERAPIES TO CNIs
High-dose corticosteroids. There is very low–quality evi-
dence that extended courses of oral or i.v. corticosteroids,
following a traditional initial steroid regimen, may increase
Table 5 | CNI trials in SRNS
Author N Intervention Control
Treatment
duration
(months)
Remission: complete
or partial RR for remission Conclusion
Lieberman 1996109 24 Cyclosporine Placebo 6 12 (100%) vs. 2 (17%) 5.48 (1.95–15.44) Remission
cyclosporine4placebo
Ponticelli 1993110 17a Cyclosporine Supportive therapy 12b 6 (60%) vs. 0 (0%) 9.45 (0.62–1.51) Remission
cyclosporine4control
Garin 1988108 8 Cyclosporine None 2 0 (0%) vs. 0 (0%) 0 (0.0–0.0) No significant difference
Choudhry 2009113 41 Tacrolimusþ
prednisone
Cyclosporineþ
prednisone
12 18 (86%) vs. 15 (75%) 1.14 (0.84–1.55) No significant difference
Gipson 2011111 138 Cyclosporine MMFþDexamethasone 12 33 (45.8%) vs. 22 (33%) 1.35 (0.90–2.10) No significant difference
CNI, calcineurin inhibitor; SRNS, steroid-resistant nephrotic syndrome; RR, relative risk.
aChildren.
bSix months full dose followed by taper 25% every 2 months.
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the likelihood of remission. In one study, children with
SRNS, defined as resistant to 4 weeks daily and 4 weeks
alternate day prednisone, received i.v. corticosteroids
(methylprednisolone or dexamethasone) for 6 doses com-
bined with oral prednisone, and the short-term outcome was
assessed at the end of a 2-week regimen. Because only a
minority of those randomized to methylprednisolone actually
received that agent, the study is of very low quality. The
remaining patients were treated with dexamethasone.
Of the 81 subjects treated, 78 were evaluated in the results.
The corticosteroid pulse therapy induced a 34% complete
remission and 13% partial remission with no significant
difference between methylprednisolone and dexamethasone
treatment groups.117 The remission response rates from
low-dose corticosteroids in small randomized studies in
SRNS are summarized in Table 6, and suggest that up to 53%
of patients with SRNS achieve remission with extended
steroid therapy; 0-17% (mean 8%) achieve remission with no
additional therapy.
MMF. A single RCT evaluated MMF in combination
with oral dexamethasone vs. cyclosporine. Patients in the
MMF arm of this trial had a 33% combined complete and
partial remission rate with 12 months of therapy. The study
did not demonstrate a significant difference between the
treatment arms (see Table 5).111 Similarly, observational
studies involving children with SRNS who were treated for
a minimum of 6 months with mycophenolate demonstrated
a complete remission rate from 23% to 62%, a partial
remission rate of 25% to 37% and no remission in 8% to
40%.116,118
Cytotoxic agents. There is moderate evidence to suggest
that cytotoxic agents in children with SRNS should not be
used, based upon two randomized controlled trials that show
no evidence of benefit of these agents combined with
prednisone, compared to corticosteroids alone. The evidence
is of moderate quality due to the small sample size
(Table 7).97,98 In the ISKDC trial, there was no significant
difference in achieving a complete remission with cyclophos-
phamide therapy plus corticosteroids compared to corticos-
teroids alone with 10/18 vs. 6/13 achieving complete
remission in the combined-therapy group vs. corticosteroids
alone group and an increase in adverse events.119 Although
imprecision may affect this risk estimate, the RR and CI are
centered around 1. In the Tarshish trial comparing cyclopho-
sphamide plus corticosteroids vs. corticosteroids alone, there
was also no evidence of benefit with the addition of
cyclophosphamide, i.e., 16/32 with combination vs. 12/21
monotherapy (P¼NS). One additional randomized trial
compared cyclophosphamide (N¼ 17) to cyclosporine
(N¼ 15). The study was halted at week 12 according to
predefined stopping rules, due to the significant difference
between the combined complete and partial remission rates
of 60% in cyclosporine group and 17% in the cyclophos-
phamide group (P o0.05).120 At the present time, the
potential harm from cytotoxic agents—including serious
infections, increased risk for late onset malignancy, reduced
fertility, hemorrhagic cystitis, and alopecia—far exceeds any
evidence of benefit (Online Suppl Table 14).43
Rituximab. Rituximab is not recommended as a treat-
ment option for SRNS due to the lack of RCTs and risk
for serious adverse events, which may persist long after
the discontinuation of the therapy.82 Although this may
be a promising agent, prospective randomized studies are
required.
Table 6 | Remission in corticosteroid-treated control arms of SRNS randomized trials
Trial Treatment Remission outcome Events Total N Response (%)
ISKDC 197497 Prednisone Complete 6 13 46.2
Tarshish 199698 Prednisone Complete or partial 12 21 57.1
Prednisone response Complete or partial 18 34 52.9
Lieberman 1996109 Placebo Partial 2 12 16.7
Ponticelli 1993110 No Steroids Complete or partial 0 7 0.0
Garin 1988108 Placebo Complete 0 4 0.0
No prednisone response Complete or partial 2 23 8.7
ISKDC, International Study of Kidney Disease in Children; SRNS, steroid-resistant nephrotic syndrome.
Table 7 | Cytotoxic therapy in SRNS
Author N Intervention Control
Remission complete
or partial
RR for
remission Conclusion
ISKDC 197497 31 Cyclophosphamide p.o. + prednisone 3 mo Prednisone 3 mo 10 (56%) vs. 6 (46%) 1.20 (0.59–2.47) ND
Tarshish 199698 53 Cyclophosphamide po x 3 mo + prednisone
12 mo q.o.d.
Prednisone
12 mo q.o.d.
16 (50%) vs. 12 (57%) 0.88 (0.53–1.45) ND
ISKDC, International Study of Kidney Disease in Children; ND, not determined; p.o., orally; q.o.d., every other day; SRNS, steroid-resistant nephrotic syndrome.
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Relapsing Disease
In SRNS patients with relapse after complete remission,
we suggest that immunosuppressant therapy be reinstated.
This recommendation is based upon the concern that
uncontrolled SRNS is likely to lead both to complications
from the persistent nephrotic state as well as a high risk for
kidney failure. We have no evidence in the literature to
support a specific treatment choice. Options are provided
without prioritization, and include oral corticosteroids, a
return to the previously effective immunosuppressant agent,
or the selection of an alternate immunosuppressant agent
to avoid potential toxicity. Assessment of risk vs. benefit
needs reassessment and becomes more relevant with each
relapse.
RESEARCH RECOMMENDATIONS
K RCTs are needed in resistant nephrotic syndrome
comparing CNIs to alternate immunosuppressive and
nonimmunosuppressive agents.
K Investigation of treatment options is needed for
patients with nephrotic syndrome associated with genetic
mutations.
K RCTs are needed examining rituximab therapy for SRNS.
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